SR-717

  Cat. No.:  DC39030   Featured
SR-717
Chemical Structure
2375420-34-9
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
SR-717 is a non-nucleotide, small-molecule STING agonist and functions as a direct cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) mimetic that induces the same "closed" conformation of STING.SR-717 functions as a direct cyclic guanosine monophosphate–adenosine monophosphate (cGAMP) mimetic that induces the same “closed” conformation of STING. SR-717 displayed antitumor activity; promoted the activation of CD8+ T, natural killer, and dendritic cells in relevant tissues; and facilitated antigen cross-priming. SR-717 also induced the expression of clinically relevant targets, including programmed cell death 1 ligand 1 (PD-L1), in a STING-dependent manner.
Cas No.: 2375420-34-9
Chemical Name: Benzoic acid, 4,​5-​difluoro-​2-​[[[6-​(1H-​imidazol-​1-​yl)​-​3-​pyridazinyl]​carbonyl]​amino]​-
Synonyms: SR717,SR 717,SR-717
SMILES: O=C(C1C(NC(=O)C2C=CC(N3C=NC=C3)=NN=2)=CC(F)=C(F)C=1)O[Li]
Formula: C15H8F2LiN5O3
M.Wt: 351.193
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication: [1] Gajewski and Higgs, (2020). Immunotherapy with a sting. Science, DOI: 10.1126/science.abc6622. [2] Chin et al, (2020). Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic. Science, 10.1126/science.abb4255 [3] Pan et al, (2020). An orally available non-nucleotide STING agonist with antitumor activity. Science, https://doi.org/10.1126/science.aba6098
Description:
In Vivo:
In Vitro:
References:
Kinase Assay:
Cell Assay:
Animal Administration:
References:
MSDS
TITLE DOWNLOAD
MSDS_20444_DC39030_2375420-34-9
COA
LOT NO. DOWNLOAD
Cat. No. Product name Field of application
DC39031 MSA-2 MSA-2 is an orally available human STING agonist.MSA-2 is bound to STING as a noncovalent dimer. Extensive experimental analysis indicates that MSA-2 predimerization is required for binding. Acidic tumor microenvironments favor permeable, uncharged MSA-2. Intracellular MSA-2 is "trapped" and accumulation drives MSA-2 dimerization, preferentially activating STING intratumorally. Orally dosed MSA-2 is well tolerated in mice, exhibiting STING-dependent antitumor activity, as monotherapy and combined with antibodies against PD1 (anti-PD1).
DC39030 SR-717 SR-717 is a non-nucleotide, small-molecule STING agonist and functions as a direct cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) mimetic that induces the same "closed" conformation of STING.SR-717 functions as a direct cyclic guanosine monophosphate–adenosine monophosphate (cGAMP) mimetic that induces the same “closed” conformation of STING. SR-717 displayed antitumor activity; promoted the activation of CD8+ T, natural killer, and dendritic cells in relevant tissues; and facilitated antigen cross-priming. SR-717 also induced the expression of clinically relevant targets, including programmed cell death 1 ligand 1 (PD-L1), in a STING-dependent manner.
DC22331 STING agonist compound 3 STING agonist-3, compound 3, is a selective and non-nucleotide small-molecule STING agonist, which has durable anti-tumor effect and tremendous potential to improve treatment of cancer.
DC11451 STING agonist compound 1 diABZI STING agonist-1 is a selective stimulator of interferon genes (STING) receptor agonist, with EC50s of 130, 186 nM for human and mouse, respectively.
DC26063 STING Agonist C11 STING agonist C11 is an agonist of the stimulator of interferon genes (STING) pathway.